Owens & Minor (NYSE:OMI) Reaches New 52-Week Low – Should You Sell?

Shares of Owens & Minor, Inc. (NYSE:OMI) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $7.24 and last traded at $7.23, with a volume of 91602 shares. The stock had previously closed at $7.45.

Analysts Set New Price Targets

OMI has been the subject of several research analyst reports. Robert W. Baird decreased their price target on shares of Owens & Minor from $15.00 to $14.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. UBS Group decreased their price target on shares of Owens & Minor from $25.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Citigroup decreased their price target on shares of Owens & Minor from $21.00 to $18.50 and set a “buy” rating for the company in a research note on Tuesday, November 5th. Finally, Barclays decreased their price target on shares of Owens & Minor from $18.00 to $14.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 5th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $16.79.

Owens & Minor Stock Performance

The company’s fifty day simple moving average is $12.53 and its 200 day simple moving average is $13.69. The company has a current ratio of 1.09, a quick ratio of 0.45 and a debt-to-equity ratio of 2.11. The stock has a market capitalization of $543.39 million, a P/E ratio of -10.84, a P/E/G ratio of 0.25 and a beta of 0.48.

Insider Transactions at Owens & Minor

In other news, CFO Jonathan A. Leon sold 5,282 shares of Owens & Minor stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $11.82, for a total transaction of $62,433.24. Following the completion of the sale, the chief financial officer now directly owns 130,822 shares of the company’s stock, valued at approximately $1,546,316.04. The trade was a 3.88 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 3.59% of the stock is currently owned by insiders.

Institutional Trading of Owens & Minor

A number of hedge funds have recently made changes to their positions in OMI. FMR LLC lifted its stake in Owens & Minor by 0.8% in the third quarter. FMR LLC now owns 11,564,624 shares of the company’s stock worth $181,449,000 after purchasing an additional 90,862 shares during the last quarter. Vanguard Group Inc. lifted its stake in Owens & Minor by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 8,915,756 shares of the company’s stock worth $116,529,000 after purchasing an additional 107,092 shares during the last quarter. Coliseum Capital Management LLC lifted its stake in Owens & Minor by 31.3% in the fourth quarter. Coliseum Capital Management LLC now owns 4,785,964 shares of the company’s stock worth $62,553,000 after purchasing an additional 1,141,483 shares during the last quarter. State Street Corp lifted its stake in Owens & Minor by 2.6% in the third quarter. State Street Corp now owns 3,064,547 shares of the company’s stock worth $48,083,000 after purchasing an additional 78,985 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Owens & Minor by 13.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,305,043 shares of the company’s stock worth $30,127,000 after purchasing an additional 276,807 shares during the last quarter. 98.04% of the stock is owned by institutional investors.

About Owens & Minor

Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments.